A44 cancel

in cell adhesion and leucine-rich repeats participate in protein-protein interactions. It is understood that the transmembrane domains may be removed to create soluble proteins herein. –

Please replace the paragraph beginning at page 51, line 13, with the following rewritten paragraph:

A45

– In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins", "breast cancer modulating proteins" "BCP" or a "BCMP". In one embodiment, BCMP is termed BCH1. In one embodiment, BCH1 can be identified as described for identifying breast cancer proteins herein. In a preferred embodiment, BCH1 is depicted in Figure 34 (SEQ ID NO:25). The BCMP may be a fragment, or alternatively, be the full length protein to the fragment shown herein. Preferably, the BCMP is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. –

On page 65, immediately preceding the claims, please insert the enclosed text entitled "SEQUENCE LISTING".

IN THE CLAIMS:

Please replace Claim 11 with the following rewritten claim:

A46

– 11. The antibody of Claim 10 wherein said fragment is BCH1p1 (SEQ ID NO:26) or BCH1p2 (SEQ ID NO:27). –

Please replace Claim 19 with the following rewritten claim:

A47

– 19. The method of Claim 16 wherein said fragment is selected from the group consisting of BCH1p1 (SEQ ID NO:26) and BCH1p2 (SEQ ID NO:27). –

Please replace Claim 23 with the following rewritten claim: